( NASDAQ-NMS:RIGL )

News from Rigel Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 17, 2017, 16:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on November 7, 2017 and November 13, 2017 the Compensation Committee of Rigel's Board of...


Nov 07, 2017, 16:01 ET Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2017. Recent...


Nov 02, 2017, 07:30 ET Rigel Welcomes Gregg Lapointe to Board of Directors

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Gregg Lapointe, CPA, MBA has been appointed to Rigel's board of directors. Currently...


Oct 31, 2017, 07:30 ET Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter financial results after market close on Tuesday,...


Oct 10, 2017, 16:01 ET Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000...


Oct 04, 2017, 22:36 ET Rigel Announces Pricing Of Public Offering Of Common Stock

Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 18,100,000...


Oct 03, 2017, 16:01 ET Rigel Announces Proposed Public Offering Of Common Stock

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an...


Oct 03, 2017, 07:30 ET Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the company recently completed enrollment of Stage 1 of its Phase 2, open-label,...


Oct 02, 2017, 07:30 ET Rigel Provides Update on FDA Review of Fostamatinib for ITP

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that during the company's mid-cycle meeting with the U.S. Food and Drug Administration...


Sep 19, 2017, 07:30 ET Rigel to Present at Cantor Fitzgerald Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled...


Aug 25, 2017, 07:30 ET Rigel Welcomes Brian Kotzin, M.D. to Board of Directors

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A...


Aug 18, 2017, 16:02 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on August 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the...


Aug 01, 2017, 16:01 ET Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2017. Recent...


Jul 25, 2017, 07:30 ET Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter financial results after market close on Tuesday,...


Jun 22, 2017, 16:05 ET Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that data from its FIT Phase 3 clinical program evaluating the safety and efficacy of...


Jun 19, 2017, 07:30 ET FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for...


Jun 01, 2017, 07:30 ET Rigel to Present at Jefferies 2017 Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a...


May 02, 2017, 16:01 ET Rigel Announces First Quarter 2017 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2017. Recent Achievements...


Apr 27, 2017, 07:30 ET Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the...


Apr 25, 2017, 07:30 ET Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2017 financial results after market close on...


Apr 17, 2017, 16:05 ET Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...


Mar 07, 2017, 16:01 ET Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2016. Recent...


Feb 28, 2017, 07:30 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2016 financial results after market...


Feb 03, 2017, 16:01 ET Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the closing of its previously announced underwritten public offering of 23,000,000...


Jan 31, 2017, 07:30 ET Rigel Announces Pricing Of Public Offering Of Common Stock

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 20,000,000...